Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLM plus cytarabine pharmacokinetic study in children with newly diagnosed AML
ChiCTR2300067964Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone, cytarabine and etoposide in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Pharmacokinetic characteristics of PLM after first administration. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
mitoxantronecytarabineetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300067964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067964.